Viracta Therapeutics, Inc. stock is down -17.44% since 30 days ago. The next earnings date is Mar 11, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.11% of the previous 18 November’s closed higher than October. 100% of analysts rate it a buy.
Viracta Therapeutics, Inc. engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir. The company's development pipeline includesvecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510.